Skip to main content

Table 2 Univariate analysis of LPNM for 73 patients after nCRT

From: Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis

Variables

Positive LPN

(n = 15)

Negative LPN

(n = 58)

P

Gender

  

0.493

 Male

10 (66.7)

33 (56.9)

 

 Female

5 (33.3)

25 (43.1)

 

Age (years)

  

0.786

  ≤ 60

9 (60.0)

37 (63.8)

 

  > 60

6 (40.0)

21 (36.2)

 

Distance from the AV (cm)

  

0.923

 < 5

9 (60.0)

34 (58.6)

 

 5–10

6 (40.0)

24 (41.4)

 

Post-nCRT LPN short diameter (mm)

  

 < 0.001

 < 7

1 (6.7)

44 (75.9)

 

 ≥ 7

14 (93.3)

14 (24.1)

 

LPN intensity

  

0.141

 Normal

7 (46.7)

39 (67.2)

 

 Inhomogeneous or intense enhancement

8 (53.3)

19 (32.8)

 

LPN shape

  

0.046

 Normal

5 (33.3)

36 (62.1)

 

 Irregular shape or rough edges

10 (66.7)

22 (37.9)

 

Pre-nCRT CEA level (ng/ml)

   

 < 5

12 (80.0)

49 (84.5)

0.979

 ≥ 5

3 (20.0)

9 (15.5)

 

ypT stage

  

0.025

 T1–2

2 (13.3)

26 (44.8)

 

 T3–4

13 (86.7)

32 (55.2)

 

ypN stage

  

0.080

 N0

5 (33.3)

34 (58.6)

 

 N1–2

10 (66.7)

24 (41.4)

 

Mesorectal LN metastasis

3.4 ± 6.2

1.4 ± 2.5

0.151

Histology

  

0.027

 Moderate

9 (60.0)

50 (86.2)

 

 Poor/Mucinous/signet adenocarcinoma

6 (40.0)

8 (13.8)

 

 Lymphatic invasion

8 (53.3)

9 (15.5)

0.006

 Perineural invasion

7 (46.7)

16 (27.6)

0.269

 Vascular invasion

5 (33.3)

11 (19.0)

0.396

Types of operation (%)

  

0.771

 Low anterior resection

6 (40.0)

20 (34.5)

 

 Abdominoperineal resection

8 (53.3)

36 (62.1)

 

 Hartmann procedure

1 (6.7)

2 (3.4)

 

LPND type (%)

  

1.000

 Unilateral dissection

11 (73.3)

44 (75.9)

 

 Bilateral dissection

4 (26.7)

14 (24.1)

 

Adjuvant chemotherapy

13 (86.6)

41 (70.7)

0.296

  1. SD standard deviation, BMI body mass index, AV anal verge, LPN, lateral pelvic lymph node, LPNM lateral pelvic lymph node metastasis, LPND lateral pelvic lymph node dissection